Featured Press Releases

AISA Pharma receives FDA orphan drug designation for AISA-021, a treatment for systemic sclerosis

AISA Pharma receives FDA orphan drug designation for AISA-021, a treatment for systemic sclerosis

nuBioAge, nuHx, and Marius Pharmaceuticals launch a collaborative GLP-1 comparison study in male patients.

nuBioAge, nuHx, and Marius Pharmaceuticals launch a collaborative GLP-1 comparison study in male patients.

  • 25 Sep 2024

nuBioAge, a longevity science and wellness network based in West Palm Beach, has announced a...

The merger with NLS Pharmaceutics was approved by Kadimastem shareholders

The merger with NLS Pharmaceutics was approved by Kadimastem shareholders

Qualia NAD+ Shown In Preliminary Clinical Study To Increase NAD+ By 85%

Qualia NAD+ Shown In Preliminary Clinical Study To Increase NAD+ By 85%

SciTech Development announces the second FDA approval of a Phase 1 A/B IND for ST-001, which now targets the treatment of relapsed/refractory small cell lung cancer, following its previous approval for the treatment of T-cell NHL

SciTech Development announces the second FDA approval of a Phase 1 A/B IND for ST-001, which now targets the treatment of relapsed/refractory small cell lung cancer, following its previous approval for the treatment of T-cell NHL

Cognito Therapeutics Presents Spectris™ Data on Brain Structural Maintenance in Alzheimer’s at AD/PD™ 2025

Cognito Therapeutics Presents Spectris™ Data on Brain Structural Maintenance in Alzheimer’s at AD/PD™ 2025

Bayer’s AMBELVIST® (gadoquatrane) Gains FDA Approval for Contrast-Enhanced MRI in Detection of Lesions with Abnormal Vascularity Across CNS and Non-CNS Body Regions

Bayer’s AMBELVIST® (gadoquatrane) Gains FDA Approval for Contrast-Enhanced MRI in Detection of Lesions with Abnormal Vascularity Across CNS and Non-CNS Body Regions

  • Bayer
  • 15 Jun 2026
EVERY and Huvepharma Announce Fourfold Expansion of Production Capacity

EVERY and Huvepharma Announce Fourfold Expansion of Production Capacity

  • The EVERY Company
  • 15 Jun 2026
Results from Incyte’s Phase 3 frontMIND Trial of Tafasitamab Combination Show Prolonged Progression-Free Survival Presented at EHA 2026

Results from Incyte’s Phase 3 frontMIND Trial of Tafasitamab Combination Show Prolonged Progression-Free Survival Presented at EHA 2026

  • Incyte
  • 15 Jun 2026
AbbVie Presents EHA 2026 Data on VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Nine-Year Outcomes

AbbVie Presents EHA 2026 Data on VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Nine-Year Outcomes

  • AbbVie
  • 12 Jun 2026
Leading Dermatologist Dr. Dendy Engelman Joins ELASTEN® to Advance the Future of Science-Backed Skin Health from Within

Leading Dermatologist Dr. Dendy Engelman Joins ELASTEN® to Advance the Future of Science-Backed Skin Health from Within

  • QUIRIS Healthcare
  • 11 Jun 2026
Breast Milk–Inspired Synbiotic for Infant Gut Health Developed Through Partnership Between NurtureBio and Lallemand

Breast Milk–Inspired Synbiotic for Infant Gut Health Developed Through Partnership Between NurtureBio and Lallemand

  • NurtureBio
  • 11 Jun 2026
The Digital Pharma Advances Conference 2026

Most Popular
June   2026
M T W T F S S
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30          

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.